MRI of hypertrophic cardiomyopathy: Part I, MRI appearances

American Journal of Roentgenology

Volumn 189, Issue 6, 2007, Pages 1335-1343

  Hansen, Mark W ^a,b   Merchant, Naeem ^b  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cardiac imaging; Cardiomyopathy; Cardiovascular imaging; Heart disease; Hypertrophic cardiomyopathy; Mitral valve; MRI

Indexed keywords

GADOLINIUM;

HEART DEATH; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 36448961947     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.2286     Document Type: Review

References (44)

1. Hansen MW, Merchant N. MRI of hypertrophic cardiomyopathy: part 2, differential diagnosis, risk stratification, and posttreatment MRI appearances. AJR 2007; 189:1344-1352
2. Kovacic JC, Muller D. Hypertrophic cardiomyopathy: state-of-the-art review, with focus on the management of outflow obstruction. Intern Med J'2003; 33:521-529
3. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363:1881-1891
4. Hughes SE. The pathology of hypertrophic cardiomyopathy. Histopathology 2004; 44:412-427
5. Wigle ED. Cardiomyopathy: the diagnosis of hypertrophic cardiomyopathy. Heart 2001; 86:709-714
6. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93:841-842
7. Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001; 38:315-321
8. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998; 338:1248-1257
9. Mozaffarian D, Caldwell JH. Right ventricular involvement in hypertrophic cardiomyopathy: a case report and literature review. Clin Cardiol 2001; 24:2-8
10. Sipola P, Lauerma J, Jääskeläinen P, et al. Cine MR imaging of myocardial contractile impairment in patients with hypertrophic cardiomyopathy attributable to Asp175Asn mutation in the alpha-tropomyosin gene. Radiology 2005; 236:815-824
11. Pons-Lladó G, Carreras F, Bórras X, et al. Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging. Am J Cardiol 1997; 79:1651-1656
12. Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005; 112:855-861
13. Prasad K, Atherton J, Smith GC, McKenna WJ, Frenneaux MP, Nihoyannopoulos P. Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy. Heart 1999; 82[suppl 3]:III8-III15
14. Li W, Stern JS, Mai VM, Pierchala LN, Edelman RR, Prasad PV. MR assessment of left ventricular function: quantitative comparison of fast imaging employing steady-state acquisition (FIESTA) with fast gradient echo cine technique. J Magn Reson Imaging 2002; 16:559-564
15. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson 2005; 7:775-782
16. Kacere RD, Perevra M, Nemeth MA, Muthupillai R, Flamm SD. Quantitative assessment of left ventricular function: steady-state free precession MR imaging with or without sensitivity encoding. Radiology 2005; 235:1031-1035
17. Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38:1701-1706
18. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003; 41:987-993
19. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348:295-303
20. Macgowan CK, Kellenberger CJ, Detsky JS, Roman K, Yoo SJ. Real-time Fourier velocity encoding: an in vivo evaluation. J Magn Reson Imaging 2005; 21:297-304
21. Moon JC, Mogensen J, Elliott PM, et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 2005; 91:1036-1040
22. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41:1561-1567
23. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000; 35:36-44
24. Tani T, Tanabe K, Ono M, et al. Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2004; 17:644-648
25. Satoh T, Zipes DP. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7:833-842
26. Sperling RT, Parker JA, Manning WJ, Danias PG. Apical hypertrophic cardiomyopathy: clinical, electrocardiographic, scintigraphic, echocardiographic, and magnetic resonance imaging findings of a case. J Cardiovasc Magn Reson 2002; 4:291-295
27. Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart 2004; 90:645-649
28. Eriksson MJ, Sonnenberg B, Woo A, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39:638-645
29. Bergey PD, Axel L. Focal hypertrophic cardiomyopathy simulating a mass: MR tagging for correct diagnosis. AJR 2000; 174:242-244
30. Kawashima T, Yokota Y, Yokoyama M, Itoh H. Pathological analysis of hypertrophic cardiomyopathy simulating dilated cardiomyopathy. Acta Pathol Jpn 1993; 43:304-312
31. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987; 60:123-129
32. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 2001; 218:215-223
33. Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology 2001; 218:703-710
34. Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation 1996; 94:3318-3326
35. Teraoka K, Hirano M, Ookubo H, et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 2004; 22:155-161 [Erratum in Magn Reson Imaging 2004; 22:901]
36. Papavassiliu T, Schnabel P, Schröder M, Borggrefe M. CMR scarring in a patient with hypertrophic cardiomyopathy correlates well with histological findings of fibrosis. Eur Heart J 2005; 26:2395
37. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 43:2260-2264
38. Anderson KR, Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol 1979; 128:79-85
39. Kim RJ, Judd RM. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death? J Am Coll Cardiol 2003; 41:1568-1572
40. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005; 26:1461-1474
41. Bogaert J, Goldstein M, Tannouri F, Golzarian J, Dymarkowski S. Late myocardial enhancement in hypertrophic cardiomyopathy with contrast-enhanced MR imaging. AJR 2003; 180:981-985
42. Amano Y, Kumita S, Takayama M, Kumazaki T. Comparison of contrast-enhanced MRI with iodine-123 BMIPP for detection of myocardial damage in hypertrophic cardiomyopathy. AJR 2005; 185:312-318
43. Amano Y, Takayama M, Takahama K, Kumazaki T. Delayed hyper-enhancement of myocardium in hypertrophic cardiomyopathy with asymmetrical septal hypertrophy: comparison with global and regional cardiac MR imaging appearances. J Magn Reson Imaging 2004; 20:595-600
44. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357:420-424